Covance Central Laboratory Receives CAP Accreditation in China
April 06 2009 - 10:42AM
PR Newswire (US)
- Covance's fourth CAP-accredited central laboratory advances
patient safety, R&D efficiency - PRINCETON, N.J., April 6
/PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced
that the company's Shanghai, China central laboratory has achieved
accreditation by the College of American Pathologists (CAP). With
CAP accreditation, Covance's Shanghai central laboratory joins an
exclusive group of international laboratories that meet the highest
standards of excellence to improve patient safety and speed drug
development. Based on rigorous accreditation standards, the CAP
Laboratory Accreditation Program is the only internationally
recognized program that utilizes teams of practicing laboratory
professionals as inspectors. Designed to go well beyond regulatory
compliance, the program helps laboratories achieve the highest
standards of excellence to positively impact patient care. The
inspection process includes a quality practice blueprint for
laboratories to follow, which is also used by inspection teams to
assess the overall management and operation of the laboratory.
Because of its comprehensive nature, CAP accreditation is designed
to improve patient safety by advancing the quality of pathology and
laboratory services through education, standard setting, and
ensuring laboratories meet or exceed regulatory requirements.
Covance's Shanghai central laboratory is the company's fourth
laboratory to achieve CAP accreditation and Level-1 NGSP (National
Glycohemoglobin Standardization Program) certification, a standard
requirement for drug development hemoglobin testing. Covance's
central laboratory network includes dedicated facilities in
Indianapolis, Indiana; Geneva, Switzerland; and Singapore. Each
laboratory in Covance's network uses the same technical platforms,
methods, and procedures to provide the same level of quality
laboratory data, regardless of location. "Covance is committed to
meeting our clients' need for high quality laboratory data in all
regions of the world," said Deborah Tanner, Covance's corporate
senior vice president and president of central laboratory services.
"With the combination of our broad, expanded portfolio of
laboratory testing capabilities and CAP accreditation in China,
Covance continues to provide the industry's most comprehensive and
flexible clinical trial laboratory service solutions to the growing
numbers of sponsors conducting clinical studies in the Asia Pacific
region, and throughout the world." The Shanghai laboratory opened
in 2007 and currently offers routine chemistry, hematology,
urinalysis, immunology, special chemistry, DNA extraction, flow
cytometry, and coagulation testing services. Covance also operates
two clinical development offices in Beijing and Shanghai that
provide clients with access to large patient populations,
investigators, and sites in this key region. About Covance Covance,
with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies
with annual revenues greater than $1.7 billion, global operations
in more than 25 countries, and more than 9,600 employees worldwide.
Information on Covance's products and services, recent press
releases, and SEC filings can be obtained through its website at
http://www.covance.com/. Statements contained in this press
release, which are not historical facts, are forward-looking
statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding
anticipated trends in the Company's business are based largely on
management's expectations and are subject to an qualified by risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include, without limitation,
competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the
Company's ability to continue to attract and retain qualified
personnel, the fixed price nature of contracts or the loss of large
contracts, and other factors described in the Company's filings
with the Securities and Exchange Commission. DATASOURCE: Covance
Inc. CONTACT: Media Relations, +1-609-419-2466, Investor Relations,
+1-609-452-4807 Web Site: http://www.covance.com/
Copyright